Metrics as of 10/17/2026, 08:46 AM (Berlin time), refresh in progress.
Envista Holdings Stock
Envista Holdings Corp
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Paul A. Keel
- Employees
- 12,000
- Market cap
- $3.7 B
- IPO
- 18/09/2019
Envista Holdings Corp is a healthcare company dedicated to the development and distribution of a comprehensive range of dental solutions. The company is headquartered in Brea, USA, and operates within the medical instruments and supplies industry. With approximately 12,000 employees, the firm is listed on the NYSE.…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Envista Holdings stock: price history
1D
-2.6%
1W
-0.4%
1M
-8.3%
6M
-17.7%
YTD
+5.5%
1Y
+16.1%
2Y
+26.0%
5Y
-40.9%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~31% stronger price swings than usual
Envista Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Envista Holdings
Analyst assessment of Envista Holdings
PRICE TARGET LOW
US$23.00
CONSENSUS
US$28.60
MEDIAN
US$28.00
PRICE TARGET HIGH
US$33.00
0
STRONG BUY
8
BUY
11
HOLD
1
SELL
0
STRONG SELL
20
TOTAL · Hold
As of: 15/10/2026
Envista Holdings stock metrics
P/E
38.81
P/B
1.21
EV/EBITDA
10.14
RETURN ON EQUITY
1.7%
NET MARGIN
7.4%
DEBT/EQUITY
0.52
DIVIDEND YIELD
0.0%
AS OF
03/07/2026
Free float & liquidity
FREE FLOAT
99.5%
FLOAT SHARES
159,867,624
AVG. DAILY VOLUME (30D)
2,843,401
Insider transactions (SEC)
Acurio Veronica
Nilsson Stefan
Befidi Robert
Hammes Eric D.
Reis Mischa
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Envista Holdings stock
What does Envista Holdings do?
Envista Holdings Corp is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Paul A. Keel, the company employs around 12,000 people.
The IPO was on 18/09/2019; the stock trades on NYSE under the ticker NVST.
What do analysts say about Envista Holdings stock?
20 analysts rate the stock, the consensus is Hold (as of 15/10/2026).
The average price target is US$28.60, ranging from US$23.00 to US$33.00, with a median of US$28.00.
This is an external assessment, not a statement by Market Jury.
When does Envista Holdings report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does Envista Holdings pay a dividend?
No, Envista Holdings currently does not pay a dividend.
Which stocks are comparable to Envista Holdings?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Envista Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Envista Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.